Since HER family members transduce their mitogenic and invasive responses via combinatorial heterodimerization of HERs upon the activation of ligands to EGFR or HER3, cancer cells could manifest a full repertoire of HER signaling without co-overexpression of HER family members. The gene discussed is ERBB3; the disease is cancer.